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because surgeons do not think that this small improvement
in patency justifies the expense and technical difficulty of
using HUV. Perhaps the most important observation in
the UK randomized femoropopliteal trial was that in more
than 800 femoropopliteal grafts, the patency in above-knee
(AK) femoropopliteal bypass grafts was marginally better
with prosthetic material rather than saphenous vein, with a
cumulative patency at 3 years of 65% for prosthetic materi-
als and 62% for vein.6 There have been two prospective
randomized trials comparing PTFE with saphenous vein
and a number of nonrandomized studies in which investi-
gators also reported comparable patencies for AK pros-
thetic bypass grafts in patients taking aspirin.5,9-16
As a substantial proportion of femoropopliteal recon-
structions fail, any improvement in graft materials has
important clinical implications. With cumulative graft fail-
ures of 30% within 2 years, femoropopliteal bypass graft is
the ideal “test bed” for new vascular materials. In both
saphenous vein and prosthetic bypass grafts most graft fail-
ures occur in the first few months. For prosthetic grafts,
this failure rate is 53 per 1000 patient-months in the first
3 months, falling to 21 per 1000 at 6 to 12 months, and
around 10 per 1000 in subsequent years.6 Because there
had been no adequate randomized trials involving
Dacron, we compared collagen-coated heparin-bonded
Dacron (HBD) with PTFE. The main outcome measure
was primary patency with a minimum follow-up of 2 years.
Our philosophy was that participating surgeons were free
to choose saphenous vein whenever this was available but
that prosthetic bypass graft for the AK popliteal bypass
graft could be performed in preference to saphenous vein.
Vascular surgery is a rapidly developing speciality into
which new vascular grafts were introduced by individual
surgeons who reported excellent results, often by virtue of
unusual technical ability or careful case selection. These
retrospective personal series were usually presented in a
way that makes graft performance appear better.
Saphenous vein remains the graft of choice for small
artery bypass graft distal to the knee. When this is not avail-
able, the leading alternatives are Dacron (polyester fiber),
polytetrafluoroethylene (PTFE), and human umbilical vein
(HUV), which were initially introduced on the basis of the
results obtained by individual surgeons.1-3 Dacron was
widely abandoned for femoropopliteal bypass grafts before
the introduction of carefully controlled clinical trials, and
the choice of alternatives to saphenous vein was then
between PTFE and HUV. In randomized clinical trials,
HUV tended to achieve marginally better patency, up to 5
years, compared with PTFE.4-8 However, these results
have not greatly altered clinical practice, presumably
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Heparin-bonded Dacron or polytetrafluoroethylene
for femoropopliteal bypass grafting: A multicenter
trial
Carol Devine, BA Hons, and Charles McCollum, MD, on behalf of the North West Femoro-Popliteal
Trial Participants, Manchester, United Kingdom
Background: Dacron (polyester fiber) was largely abandoned for femoropopliteal bypass grafts 30 years ago because
saphenous vein achieved better patencies. However, in patients taking aspirin, patency in above-knee femoropopliteal
bypass grafts has recently been shown to be equivalent to that with saphenous vein. We compared heparin-bonded
Dacron (HBD) and polytetrafluoroethylene (PTFE) in a randomized multicenter trial including below-knee popliteal
or tibioperoneal trunk bypass graft where the long saphenous vein was absent or inadequate.
Methods: Over 28 months, 209 patients undergoing femoropopliteal bypass grafts (180 above-knee, 29 below-knee)
were randomized to HBD (n = 106) or PTFE (n = 103). Each patient was given aspirin (300 mg/d) before surgery,
and this continued unless the patient had intolerance to the aspirin.
Results: The mean follow-up was 42 months (range, 28-55). Fifteen (7.1%) patients died with patent grafts, and three
(1.4%) infected grafts were removed. Patency (measured with Kaplan-Meier survival analysis) at 1, 2, and 3 years for
HBD was 70%, 63%, and 55% compared with 56%, 46%, and 42%, respectively, for PTFE (P = .044). A total of 67 sec-
ondary interventions were performed on 48 thrombosed grafts; long-term patency was achieved in only three. Risk fac-
tors for arterial disease did not significantly influence patency. Amputations have been performed in 23 patients, six
after HBD and 17 after PTFE bypass grafts (P = .015).
Conclusions: HBD achieved better patency than PTFE, which carried a high risk of subsequent amputation. (J Vasc Surg
2001;33:533-9.)
We had two main objectives: (1) to compare patency
achieved by HBD (InterVascular, La Ciotat, France) with
PTFE (Atrium, Hudson, NH; WL Gore, Livingston,
Scotland, or Impra Ltd, Crawley, West Sussex, UK) grafts
in femoropopliteal bypass grafts and (2) to establish a
complete database on patients undergoing prosthetic
femoropopliteal bypass grafting for multivariate analysis of
the factors leading to graft occlusion.
PATIENTS AND METHODS
Ethical approval was confirmed by the local Research
Ethics Committees. All of the patients involved gave
informed consent. A trial coordinator was hired to prevent
protocol violations, to encourage complete participation,
and to independently evaluate graft patency using objec-
tive criteria.
Patients. All patients undergoing elective AK recon-
struction and those undergoing below-knee (BK) recon-
structions where saphenous vein was not available were
considered for entry with the use of the criteria listed in
Table I. Sixteen participating surgeons at hospitals in the
North West region of England submitted 352 patients for
possible recruitment to this trial.
For the purpose of this trial, femoropopliteal bypass
graft was defined as the insertion of a bypass graft with the
proximal anastomosis to the common, profunda, or super-
ficial femoral artery above the adductor canal and distal
anastomosis to the popliteal artery above or below the
knee or to the tibioperoneal trunk. Reconstructions with
the proximal anastomosis above the inguinal ligament or
from the contralateral femoral artery or with distal anasto-
moses to individual calf arteries were not included. Also,
all eligible patients for whom distal anastomosis was
planned to be above the knee joint could be randomized
for the primary insertion of either HBD or PTFE, even
where the saphenous vein was considered adequate for
use. Where reconstruction was to be performed to the
popliteal artery below the knee or the tibioperoneal trunk,
then randomization was only appropriate when the ipsilat-
eral saphenous vein was known to be absent or was found
to be inadequate for reconstruction.
Preoperative assessment. Each patient underwent a
detailed preoperative evaluation by the trial coordinator;
medical history, details of previous surgery, symptoms of
peripheral arterial disease (claudication, rest pain, ulcera-
tion, gangrene), smoking history, and drug therapy were
all recorded. Peripheral pulses were coded as 2 (normal),
1 (weak), and 0 (absent), and ankle brachial pressure
indices (ABPIs) were recorded with a handheld Doppler
(Huntleigh Diagnostics, Cardiff, UK). Angiograms were
examined, and the number of calf arteries patent to the
ankle was recorded. Preoperative venous blood was sam-
pled for glucose, fibrinogen, cholesterol, triglycerides,
hemoglobin, and white cell and platelet counts. All
patients were prescribed aspirin (300 mg/d), unless they
could not tolerate aspirin.
Randomization. The trial coordinator was informed
about any patient scheduled for femoropopliteal bypass
grafting, for whatever reason and regardless of the avail-
ability of saphenous vein. Once consent had been
obtained, the medical history taken, and preoperative
investigations recorded, the coordinator would then
deliver the randomization envelopes (one for AK, one for
BK) to the vascular surgeon before surgery. Random-
ization, stratified for AK or BK and by the surgeon, was
performed with a dedicated computer program held by
the trial coordinator. Patients for whom a graft was to be
implanted with a distal anastomosis in the popliteal artery
above the knee were identified by the consecutive num-
bers AK1, AK2, AK3, etc. For surgeons planing to use a
prosthetic graft regardless of the adequacy of the long
saphenous vein, this sealed envelope was opened immedi-
ately before surgery. Patients for whom the distal anasto-
mosis was planned to the BK popliteal artery or
tibioperoneal trunk were identified by the consecutive
numbers BK1, BK2, BK3, etc. The sealed envelope was
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Table I. Inclusion and exclusion criteria
Inclusion criteria
Scheduled to undergo elective femoropopliteal reconstruction for occlusive arterial disease of the superficial femoral or popliteal 
artery with ipsilateral disabling intermittent claudication, rest pain, ischemic ulceration of the distal limb, or gangrene with an
ankle/brachial pressure ratio < 0.8 at rest.
Fully informed consent given in writing.
Exclusion criteria
Emergency surgery for trauma, acute thrombosis, embolism, or popliteal artery thrombosis.
Symptoms not sufficiently severe to disrupt lifestyle or ankle/brachial pressure ratio > 0.8 at rest (unless aneurysm).
The diagnosis or treatment for malignancy within 12 months including all cases with residual malignancy being followed up or
observed.
Hospital inpatient treatment for cardiac failure in the previous 6 months.
Where adequate follow-up would be impossible to arrange because the patient lived or was moving to an area where indepen
dent follow-up could not be arranged.
Table II. Objective criteria for assessment of patency
Palpable pulsation of the graft with a definite distal pulse. In
all other cases an objective investigation applied:
Duplex Doppler imaging
Angiography or digital subtraction angiography
Isotope angiography
Exploration of the graft where clinically indicated
then opened in the operating theater only after the long
saphenous vein had been found to be inadequate.
Follow-up. The trial coordinator followed up all
patients at three monthly intervals for 1 year and six
monthly intervals thereafter, either by attending outpa-
tient clinics or visiting patients at home. At each visit, fur-
ther detailed records were taken documenting changes in
medical history, smoking habits, drug therapy, and current
symptoms. Graft patency was independently assessed by
means of objective criteria (Table II).
Sample size, trial end points, and statistical analy-
sis. Sample size was based on the assumption that a one-
third reduction (33%) in failure with either material would
be clinically important. To achieve an 80% power to iden-
tify this difference at the conventional 5% significance, 126
patients would need to be recruited to each treatment
group. The withdrawal of a number of patients has
resulted in a power of 72% (based on our original assump-
tions and the number of patients finally recruited).
The principal outcome measure was primary patency,
defined as the time to first graft occlusion. Secondary
patency was defined as the time to final occlusion of the
original graft despite secondary procedures. Secondary
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patency was not accepted if a substantial proportion of the
original graft had to be replaced or bypassed.
Risk factors in the two treatment groups were tested
with χ2 analysis to check the effectiveness of randomiza-
Table III. Reasons for not randomizing patients (n = 143)
Reason for nonrandomization No. %
Alternative operation 26 18
Problems with consent (refusal, not requested before surgery) 29 20
Consented but died before bypass graft 2 1.4
Emergency surgery 1 0.7
Protocol exclusion (violation, age, malignancy) 24 17
Exploration only or operation abandoned 8 5.6
Surgery canceled (symptoms improved) 24 17
Vein bypass graft 29 20
Table IV. Risk factors
Risk factor HBD (n = 106) PTFE (n = 103) P value
Age (y) (range) 61.1 (32.9-83.3) 65.2 (35.3-86) .429
Angina/myocardial infarction 29.2% 31.1% .893
ABPI (% < mean 0.53) 49% 44.8% .650
Cardiac failure 8.7% 9.6% .867
Carotid disease 17% 19.4% .782




Hypertension 36.8% 35% .894
Hyperlipidemia 13.2% 6.8% .190
Patent calf arteries (> 2) 83.7% 79.7% .072





Indication for surgery .494
Claudication 31.1% 35.9%
Critical ischemia 68.9% 64.1%
Table V. Postoperative complications
Complication HBD PTFE Total
Hematoma 2 5 7
Infection 13 6 19
Lymphedema 11 4 15
Cellulitis 1 2 3
Hemorrhage 2 1 3
Pyrexia (unknown origin) 1 2 3
Anemia 1 1 2
Cerebrovascular accident 1 –– 1
Acute retention 1 –– 1
Dehydration 1 –– 1
Chest infection 1 2 3
Toe debridement 1 –– 1
Painful calf 1 –– 1
Pressure sore on heel 1 –– 1
Deep venous thrombosis 1 –– 1
Total 39 28 67
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Fig 1. Cumulative primary patency with life table is compared between HBD and PTFE. A, All 209 randomized grafts; B, 180 grafts
to AK popliteal artery; and C, 29 grafts for BK popliteal artery. Larger percentage numbers refer to cumulative patency at 1 and 3 years





tion. The difference in patency between the two graft
materials was compared with the Kaplan-Meier life-table
method and analyzed statistically with the log-rank test.
The influence of the various risk factors on patency was
examined with multivariate analysis. The design and analy-
sis of the trial fulfill the objectives for clinical trials sug-
gested by statisticians in both the United Kingdom and
the United States.17,18
RESULTS
Of the 352 patients referred to the trial coordinator by
16 surgeons from the North West region of England
between October 1994 and January 1997, 209 were cor-
rectly randomized as 106 HBD and 103 PTFE (85 Impra,
7 Atrium and 11 WL Gore). Reasons for exclusion are
given in Table III. Only prosthetic grafts inserted by sur-
geons who adhered to the randomization sequence were
included in the analysis. Follow-up was for a minimum of
2 years and a mean of 42 months (range, 28-55 months).
Comparability of groups. Randomization achieved
two comparable patient groups with risk factors equally
distributed between patients randomized to HBD and
PTFE (Table IV). Preoperative symptoms were grouped
into claudication only (Fontaine II) or critical ischemia
with either rest pain or ulcers/gangrene (Fontaine III and
IV). Overall, 70 (33.5%) patients underwent surgery for
claudication (HBD 33, PTFE 37), and 139 (66.5%) had
symptoms of critical ischemia. The overall mean ABPI was
0.53 (range, 0-1.12) with that for critical ischemia only a
little lower at 0.51 because of inclusion of patients with
calcified arteries and falsely high ratios. Operations were
performed on 98 (47%) right and 111 (53%) left legs. The
common femoral artery was used for the proximal anasto-
mosis in 199 (95.2%) of cases. Arteries used for the distal
anastomosis were AK popliteal (176 [84%]), BK popliteal
(25 [12%]), and tibioperoneal trunk (3 [1.4%]) with 5
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uncertain (2.4%). A vein patch (4) or Miller cuff (6) was
used at the distal anastomosis in 10 patients (2 AK, 8 BK).
Morbidity and mortality. There was no significant
difference in the frequency of postoperative complications
occurring in 39 patients with HBD and 28 PTFE (P =
.18) (Table V). Wound morbidity (infection or edge
necrosis) accounted for 19 of these events (HBD 13,
PTFE 6). Two patients died within 30 days (operative
mortality rate, 1%), and an additional 38 (18%) patients
died during follow-up, with 15 patent grafts (HBD 11,
PTFE 4). The mean cumulative survival with life table was
93%, 88%, and 84% at 1, 2, and 3 years, respectively, and
was not influenced by the type of bypass graft.
Graft patency. Overall cumulative patency was 63%,
54%, and 48% at 1, 2, and 3 years, respectively. Patency for
AK bypass graft was markedly better at 54% by 3 years com-
pared with only 16% for BK bypass graft. A total of 106
grafts occluded (HBD 46, PTFE 60) with 75 (71%) occlud-
ing within the first 12 months; 68 occlusions were con-
firmed with arteriography, 27 with duplex Doppler
imaging, and 5 with surgical exploration. Only six occlu-
sions were not confirmed by objective testing (1 death, 2
emergency admissions, and 3 patients unwilling to be inves-
tigated). Patency in the 85 Impra grafts at 41% was not dif-
ferent than that in the 28 Atrium or Gore grafts (P = .95).
Primary patency with life table for HBD was 70%, 63%, and
55% at 1, 2, and 3 years compared with 56%, 46%, and 42%,
respectively, for PTFE (P = .044; Fig 1). The difference
between patency rates for HBD and PTFE was confined to
the AK grafts where the 3-year cumulative patency was 61%
for HBD and 46% for PTFE (P = .037; Fig 1, B). The
results for BK grafts were uniformly poor with no difference
between the materials (Fig 1, C). When patients who had
any procedure other than a common femoral artery to
above the knee or below the knee popliteal artery with a
prosthetic graft without a vein patch or cuff were excluded
Fig 2. Limb survival by life table is plotted comparing patients after femoropopliteal bypass grafting with HBD and PTFE. Major limb
amputation was significantly more frequent after PTFE bypass graft; 21% of patients had amputation by 3 years. HBD, Heparin-bonded
Dacron; PTFE, polytetrafluoroethylene.
(n = 8), the difference between patency rates for HBD and
PTFE become even more significant (P = .029).
Of the 106 occlusions, 29 (27%) patients were treated
conservatively, 20 (19%) had their randomized graft
replaced and were therefore withdrawn from further
study, 9 (9%) required immediate amputation, and 48
(45%) patients were offered a secondary procedure to con-
serve the study graft. Long-term patency was established
in only three of these patients despite 67 procedures.
These three were among the 12 offered surgical
thrombectomy, with none of the 22 treated by lysis with
or without angioplasty remaining patent up until the time
of this analysis. Secondary patency rates for HBD were
74%, 64%, and 56% compared with 60%, 49%, and 45% for
PTFE at 1, 2, and 3 years, respectively (P = .052). Com-
pliance with anticoagulation at 12 months was good with
only seven patients who did not take either aspirin or an
oral anticoagulant.
Influence of risk factors. The influence of various
arterial disease risk factors on patency (ABPI, cardiac fail-
ure, diabetes, sex, hypertension, hyperlipidemia, indica-
tion for surgery, luminal graft diameter, myocardial
infarction or angina, number of calf arteries patent to the
ankle, previous arterial surgery, smoking history, and
symptomatic carotid disease) was subjected to χ2 analysis
or t test as appropriate. We could not find any significant
influence of these risk factors on subsequent graft patency.
Amputation. Amputation was performed on 23 (11%)
patients, six after HBD bypass grafts (5 AK, 1 BK) and 17
after bypass grafts with PTFE (12 AK, 5 BK) (P = .015,
Fisher exact test) (Fig 2). The risk of amputation was
thought to be low for patients undergoing femoropopliteal
bypass grafting for intermittent claudication. However, of
the 70 patients who underwent bypass grafting for claudi-
cation, eight subsequently underwent amputation despite
attempts to reestablish patency after graft thrombosis.
Seven of these eight patients had undergone bypass graft-
ing with PTFE, which means that 18% of the 37 patients
undergoing PTFE femoropopliteal bypass grafts for inter-
mittent claudication underwent subsequent amputation
despite a mean follow-up interval of only 4 years. Of the 23
amputations, 16 were above the knee (HBD 5, PTFE 11)
and seven below the knee (HBD 1, PTFE 6).
DISCUSSION
Rather surprisingly, our results demonstrate signifi-
cantly better patencies with HBD femoropopliteal bypass
grafts than with PTFE. Since its inception in 1976, PTFE
has become the most popular prosthetic graft for infrain-
guinal surgery. However, in retrospective reviews and pre-
vious studies comparing Dacron with PTFE, researchers
report equivalent or sometimes better performances from
Dacron.19-23 Our poor results for PTFE were comparable
to those previously reported in the Medical Research
Council–funded study comparing HUV and PTFE where
primary patency for PTFE (n = 104) was reported as 61%,
56%, and 48% at 1, 2, and 3 years, respectively.6
Amputation rates in this study were no worse than
those previously published for PTFE because the Medical
Research Council study reported amputation in 23 (22%)
of PTFE grafts.6 The high amputation rate in patients
after PTFE bypass grafts in our current study included
seven patients in whom the original indication for surgery
was for claudication only. Because the risk of amputation
is low for intermittent claudication that is treated conser-
vatively, these results suggest that the risk of amputation
may be increased by femoropopliteal bypass grafts with
PTFE.
This study was conceived before the widespread adop-
tion of vein graft surveillance programs, which detect
stenoses in 25% to 30% of grafts.24,25 The adoption of such
surveillance programs may improve the patency in saphe-
nous vein bypass graft so that the vein may again be the
preferred option, even for AK bypass grafts. However, the
initial enthusiasm for vein surveillance has been dampened
by recent clinical trials in which little benefit has been
found after the introduction of surveillance, and it is
doubtful that there will be any major impact on the long-
term patency of AK vein bypass graft.24,26 Where the sur-
geon adopts a strategy of using prosthetic grafts for bypass
grafts above the knee or where the vein is absent or inade-
quate for BK femoropopliteal bypass graft, our results
demonstrate that HBD achieves better patency than PTFE.
Because our grafts were predominantly 6 mm, we
were unable to analyze the influence of graft diameter on
patency. However, where the operating surgeon had a
choice, larger diameter grafts would be more likely to be
implanted for larger patients with bigger arteries. This bias
may explain the improved patency reported by the AK
femoropopliteal study group led by Abbott et al.22
The high amputation rate after PTFE bypass grafting
is comparable to that in a previous major study and sug-
gests that this material may have unique features that
increases the risk of subsequent amputation. We can only
speculate that thrombosis of PTFE grafts may involve dis-
tal embolization.
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